Nordic Pharma Receieves CE Mark Approval for Lacrifill Canalicular Gel

Nordic Group, the parent company of Nordic Pharma, announced that its dry eye therapy Lacrifill has received CE mark approval. This regulatory milestone, which Nordic says was achieved several months ahead of schedule, allows Nordic Pharma to introduce Lacrifill across European markets, with a planned launch in the coming months. 

Lacrifill is a cross-linked hyaluronic acid gel designed to temporarily block tear drainage by occluding the canalicular system. According to Nordic, by enhancing tear film preservation, Lacrifill helps keep the eyes bathed in their own natural tears, offering an individualized approach to dry eye management. The in-office procedure provides a full fill of the canalicular system and delivers effects for up to 6 months.

With its regulatory approval secured, Nordic Pharma said it is now preparing for the commercial rollout of Lacrifill in key European markets. Further details regarding availability and distribution will be shared closer to the launch date.

Lacrifill was launched in the United States in May 2024.